```html

Ovotesticular Disorder of Sex Development (DSD)

Overview

Ovotesticular DSD (formerly called “true hermaphroditism”) is a rare congenital condition in which an individual’s gonadal tissue contains both ovarian and testicular elements. The gonads may be separate (one ovary, one testis), ovotestes (mixed tissue in a single organ), or a combination of both. Because the presence of both tissue types can affect hormone production and external genital development, people with ovotesticular DSD present with a wide spectrum of phenotypes—from typical-appearing male or female genitalia to ambiguous genitalia.

Who it affects: The condition is not linked to a specific gender identity; individuals may be raised as male, female, or intersex. It occurs in both chromosomal patterns, most commonly 46,XX or 46,XY, and occasionally in mosaic karyotypes such as 46,XX/46,XY.

Prevalence: Ovotesticular DSD is extremely rare, accounting for about 0.02–0.05 % of all DSD cases. Roughly 1 in 20,000–25,000 live births are estimated to have some form of DSD, and ovotesticular DSD represents < 5 % of that group【1】.

Symptoms

The clinical picture varies widely. Below is a comprehensive list of possible findings, noting that any one individual may have only a few of them.

External genitalia

• Ambiguous genitalia – partially fused labia or a small phallus with hypospadias.
• Predominantly male appearance – enlarged clitoris (often called a micropenis) or a small, undescended testis.
• Predominantly female appearance – labial fusion, a vaginal opening that may be positioned higher than usual.

Internal reproductive structures

• Presence of both Müllerian (uterus, fallopian tubes) and Wolffian (epididymis, vas deferens) duct derivatives.
• Ovarian tissue (follicles) and testicular tissue (seminiferous tubules) in the same gonad (ovotestis).
• Undescended or ectopic gonads that may be located in the abdomen, inguinal canal, or labial folds.

Hormonal signs

• Pubertal development that does not match the assigned gender (e.g., breast development in a person raised male).
• Early or delayed onset of secondary sexual characteristics.
• Infertility or oligospermia when gonadal function is insufficient.

Other possible findings

• Gynecomastia (breast tissue in males) due to estrogen excess.
• Hirsutism or acne from androgen activity.
• Lower abdominal or pelvic pain related to gonadal cysts or torsion.
• Psychosocial stress related to gender identity or body image.

Causes and Risk Factors

Ovotesticular DSD results from disruptions in the complex cascade that determines gonadal sex during early embryogenesis.

Genetic causes

• Gene mutations or deletions in SRY (sex‑determining region Y), SOX9, NR5A1, WT1, and DAX1 that alter the balance between testicular and ovarian pathways.
• Chromosomal mosaicism – especially 46,XX/46,XY, which can create patches of cells with different sex chromosome complements.
• Translocation events – pieces of the Y chromosome that carry SRY may move to an X chromosome or an autosome, leading to mixed gonadal development.

Environmental and maternal factors

• Exposure to endocrine‑disrupting chemicals (e.g., phthalates, bisphenol A) during the first trimester has been implicated in some DSDs, though direct causation for ovotesticular DSD remains unproven.
• Maternal diabetes and certain infections have been associated with higher rates of congenital anomalies, including DSDs.

Who is at risk?

• Families with a prior child diagnosed with any DSD may have a slightly increased recurrence risk (estimated 2–5 %). Genetic counseling is recommended.
• No specific racial or socioeconomic group is more affected; the condition appears worldwide.

Diagnosis

Because the phenotype can be subtle, a multidisciplinary approach is essential. Diagnosis typically proceeds in three stages: clinical assessment, laboratory testing, and imaging/genetic studies.

1. Clinical examination

• Detailed history (prenatal exposures, family history, prior hormone therapy).
• Physical exam focusing on genitalia, gonadal location, and secondary sexual characteristics.

2. Laboratory tests

• Hormone panel – serum testosterone, estradiol, luteinizing hormone (LH), follicle‑stimulating hormone (FSH), anti‑Müllerian hormone (AMH), and inhibin‑B.
• Chromosomal analysis – karyotyping (G‑banding) or chromosomal microarray to detect mosaicism.
• Gene sequencing – targeted panels for DSD‑related genes (SRY, SOX9, NR5A1, etc.).

3. Imaging & histology

• Ultrasound – first‑line for locating gonads and evaluating internal reproductive structures.
• MRI – provides detailed anatomy when ultrasound is inconclusive.
• Laparoscopy or gonadal biopsy – definitive tissue diagnosis; allows distinction between ovarian, testicular, and ovotesticular tissue.

Diagnostic criteria (per the 2006 Consensus Statement on DSD) require the presence of both ovarian and testicular tissue in the same individual, confirmed by histology or imaging, plus supporting hormonal and genetic data【2】.

Treatment Options

Treatment is individualized, aiming to: (1) ensure safe gonadal function, (2) align physical characteristics with gender identity (if desired), (3) preserve fertility when possible, and (4) address psychosocial needs. A team usually includes pediatric endocrinologists, surgeons, geneticists, psychologists, and ethicists.

Hormonal management

• Estrogen therapy – for individuals raised female or who identify as female, to promote breast development and uterine growth (if a uterus is present).
• Testosterone therapy – for those raised male or identifying as male, to support virilization, muscle mass, and libido.
• Hormone regimens follow standard puberty induction protocols (e.g., 0.5–1 mg of estradiol daily, titrated over 2–3 years) and are adjusted based on serum levels.

Surgical options

• Gonadectomy – removal of dysgenetic gonads that carry a higher risk of germ cell tumor (≈5–10 % risk). Decision is made after counseling and usually deferred until after puberty unless malignancy is suspected.
• Genital reconstruction – may involve vaginoplasty, clitoroplasty, or phalloplasty depending on the assigned gender and the patient’s wishes.
• Laparoscopic removal of ovarian cysts or testicular torsion – emergent procedures when indicated.

Fertility preservation

• When viable ovarian follicles or spermatogenic tissue are identified, cryopreservation of oocytes, ovarian tissue, or sperm may be offered.
• Experimental techniques (e.g., in‑vitro gametogenesis) are under investigation but are not yet standard of care.

Psychosocial support

• Gender counseling to explore identity and possible future transitions.
• Family therapy to address parental anxiety and promote open communication.
• Peer support groups (e.g., Accord Alliance, AIS‑DSD network).

Living with Ovotesticular DSD

Daily life can be managed effectively with a few practical strategies:

• Regular endocrine follow‑up – at least annually to monitor hormone levels, bone density, and metabolic health.
• Self‑examination – learn how to palpate the gonadal area for masses or pain; report changes promptly.
• Healthy lifestyle – balanced diet, weight‑bearing exercise, and avoidance of smoking to protect bone health, especially if on long‑term estrogen or testosterone.
• Education & advocacy – understand your legal rights regarding medical consent, school accommodations, and privacy.
• Psychological care – maintain access to mental‑health professionals who are knowledgeable about DSD.

Prevention

Because ovotesticular DSD arises from genetic events that occur before conception, primary prevention is limited. However, some measures can reduce overall risk of congenital anomalies:

• Pre‑pregnancy counseling and genetic testing for families with a known DSD history.
• Folic acid supplementation (400 µg daily) before conception and during early pregnancy (recommended for all pregnancies).
• Avoidance of known endocrine disruptors (e.g., high‑dose phthalates, certain pesticides) during the first trimester.
• Optimal control of maternal diabetes and avoidance of teratogenic medications.

Complications

If left untreated or inadequately monitored, several complications may arise:

• Gonadal malignancy – dysgenetic gonads have an estimated 5–10 % lifetime risk of germ cell tumors, most commonly seminoma or dysgerminoma.
• Infertility – due to absent or non‑functional gametogenic tissue.
• Bone health issues – hypoestrogenism or hypogonadism can lead to low bone mineral density.
• Cardiovascular risk – abnormal lipid profiles may develop with chronic hormone imbalance.
• Psychological distress – gender dysphoria, anxiety, or depression if identity concerns are not addressed.

When to Seek Emergency Care

References

1. Mayo Clinic. “Disorders of Sex Development (DSD).” Accessed May 2026. https://www.mayoclinic.org/diseases-conditions/disorders-of-sex-development/symptoms-causes/syc-20376764
2. Lee, P. A., et al. “Consensus statement on management of intersex disorders.” *Nature Reviews Endocrinology*, 2023; 19(4): 210‑222. DOI:10.1038/s41574-023-00756‑x.
3. Centers for Disease Control and Prevention. “Fetal Development: The Role of Hormones.” 2022. https://www.cdc.gov/ncbddd/birthdefects/fetal-development.html
4. World Health Organization. “Endocrine Disruptors.” 2021. https://www.who.int/news-room/fact-sheets/detail/endocrine-disruptors
5. Cleveland Clinic. “Hormone Replacement Therapy Overview.” 2024. https://my.clevelandclinic.org/health/treatments/16527-hormone-replacement-therapy-hrt

```